Live Breaking News & Updates on Axcan Pharmaceuticals

Stay updated with breaking news from Axcan pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Versameb AG: Versameb Names Dr. Alexandre LeBeaut as Chair of the Board of Directors

Versameb AG: Versameb Names Dr. Alexandre LeBeaut as Chair of the Board of Directors
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Alexandre Lebeaut , Stefan Klotter , Klaas Zuideveld , Vifor Pharma , Novartis Pharmaceuticals , Institute For Advanced Clinical Trials Children , Plough Research Institute , Axcan Pharmaceuticals , Chief Executive Officer , Investigational New Drug , Stress Urinary Incontinence , Schering Plough Research Institute , Chief Scientific Officer , Advanced Clinical Trials , Independent Director , Calypso Biotech , Immunorx Pharma , Lassen Sie ,

Versameb Strengthens its Board of Directors

/PRNewswire/ Versameb AG ("Versameb"), transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the. ....

City Of , United Kingdom , Buenos Aires , Distrito Federal , France General , Klaas Zuideveld , Paul Korner , Brevan Howard , Lily Geidelberg , Alexandre Lebeaut , Plough Research Institute , University Of Buenos Aires , Paris Diderot University , Ferring Pharmaceuticals , Paris Descartes University , Imperial College London , Axcan Pharmaceuticals , Clinical Medical Affairs At Axovant Gene Therapies , Institute For Advanced Clinical Trials Children , Ardelyx Inc , Stress Urinary Incontinence , Chief Executive Officer , Senior Biotechnology Analyst , Sarepta Therapeutics , Axovant Gene , Chief Medical Officer ,

Redirecting to Vifor Pharma to propose Dr Alexandre LeBeaut as Board member

Vifor Pharma to propose Dr Alexandre LeBeaut as Board member
Dr Alexandre LeBeaut to be proposed to Annual General Meeting for appointment to Board
Dr Gianni Zampieri and Gilbert Achermann will not stand for re-election
Regulatory News:
Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.
Jacques Theurillat, Chairman of Vifor Pharma, commented: “We are very pleased to nominate Alexandre LeBeaut for election to the Vifor Pharma Group Board of Directors. Dr LeBeaut has broad experience in R&D, clinical development and research/medical affairs. He will optimally complement the Board to assess Vifor Pharma’s pipeline development and clinical programs aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.” ....

France General , Alexandre Lebeaut , Vifor Pharma , Jacques Theurillat , Gilbert Achermann , Gianni Zampieri , Vifor Pharma Group Board Of Directors , Swiss Stock Exchange , Paris University , Swiss Exchange , Axcan Pharmaceuticals , Vifor Pharma Group , Ipsen Bioscience Inc , Fresenius Medical Care , Annual General Meeting , Vifor Pharma Group Board , Chief Scientific Officer , Ipsen Bioscience , Pharma Group , Vifor Fresenius Medical Care Renal Pharma , பிரான்ஸ் ஜநரல் , சுவிஸ் ஸ்டாக் பரிமாற்றம் , பாரிஸ் பல்கலைக்கழகம் , சுவிஸ் பரிமாற்றம் , அச்சு மருந்துகள் , இப்செங் உயிர் அறிவியல் இன்க் ,

Vifor Pharma to propose Dr Alexandre LeBeaut as Board member

Press release content from Business Wire. The AP news staff was not involved in its creation.
Vifor Pharma to propose Dr Alexandre LeBeaut as Board member
February 2, 2021 GMT
Regulatory News:
Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.
Jacques Theurillat, Chairman of Vifor Pharma, commented: “We are very pleased to nominate Alexandre LeBeaut for election to the Vifor Pharma Group Board of Directors. Dr LeBeaut has broad experience in R&D, clinical development and research/medical affairs. He will optimally complement the Board to assess Vifor Pharma’s pipeline development and clinical programs aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.” ....

France General , Alexandre Lebeaut , Vifor Pharma , Jacques Theurillat , Julien Vignot , Nathalie Ponnier , Gilbert Achermann , Gianni Zampieri , Vifor Pharma Group Board Of Directors , Swiss Stock Exchange , Paris University , Global Head Corporate Communications , Swiss Exchange , Axcan Pharmaceuticals , Vifor Pharma Group , Ipsen Bioscience Inc , Fresenius Medical Care , Annual General Meeting , Vifor Pharma Group Board , Chief Scientific Officer , Ipsen Bioscience , Pharma Group , Vifor Fresenius Medical Care Renal Pharma , Business Wire , பிரான்ஸ் ஜநரல் , சுவிஸ் ஸ்டாக் பரிமாற்றம் ,